Results 11 to 20 of about 9,359 (237)

Effects of insulin detemir and NPH insulin on body weight and appetite-regulating brain regions in human type 1 diabetes: a randomized controlled trial. [PDF]

PLoS ONE, 2014
Studies in rodents have demonstrated that insulin in the central nervous system induces satiety. In humans, these effects are less well established.
Larissa W van Golen, Dick J Veltman, Richard G IJzerman, Jan Berend Deijen, Annemieke C Heijboer, Frederik Barkhof, Madeleine L Drent, Michaela Diamant   +7 more
doaj   +13 more sources

From Pathophysiology to Treatment: Contemporary Approaches to CFRD in the Pediatric and Adolescent Population. [PDF]

Pediatr Diabetes
Cystic fibrosis‐related diabetes (CFRD) is the most prevalent nonrespiratory complication of cystic fibrosis (CF), with its prominence growing as survival rates improve due to advances in CFTR modulator therapies. Its prevalence increases with age, affecting nearly 50% of patients with CF (PwCF) over 30 years old.
Vuralli D.
europepmc   +2 more sources

Risk of Major Congenital Malformations or Perinatal or Neonatal Death With Insulin Detemir Versus Other Basal Insulins in Pregnant Women With Preexisting Diabetes: The Real-World EVOLVE Study

Diabetes Care, 2021
OBJECTIVE To compare the risk of severe adverse pregnancy complications in women with preexisting diabetes. RESEARCH DESIGN AND METHODS Multinational, prospective cohort study to assess the prevalence of newborns free from major congenital malformations ...
E. Mathiesen, N. Ali, A. Alibegovic, E. Anastasiou, K. Cypryk, H. D. de Valk, J. Dores, F. Dunne, M. Gall, S. D. García, H. Hanaire, L. Husemoen, M. Ivanišević, H. Kempe, D. McCance, P. Damm   +15 more
semanticscholar   +1 more source

Comparison of Once-daily versus Twice-daily Injection of Insulin Detemir in Children with Type 1 Diabetes Mellitus

Iranian Journal of Pediatrics, 2022
Background: The purpose of this study was to compare the effectiveness of once-daily versus twice-daily insulin detemir injection in children with type 1 diabetes mellitus (T1DM).
A. Setoodeh, A. Rabbani, Fatemeh Sayarifard, Z. Haghshenas, A. Sayarifard, P. Rostami, F. Abbasi, Mohadeseh Bayat, S. Amini, R. Tavakolizadeh   +9 more
semanticscholar   +1 more source

Abstract 6: Maternal efficacy, safety, and pregnancy outcomes with degludec versus detemir in the treatment of pregnant women with type 1 diabetes: An international, multicentre, randomised trial

Indian journal of endocrinology and metabolism, 2022
Background and Aims: To compare the efficacy and safety of insulin degludec (degludec) versus insulin detemir (detemir) in pregnant women with type 1 diabetes (T1D).
K. Balaji, E. R. Mathiesen1,2, R. Corcoy3, F. Dunne4, M. Ekelund5, D. S. Feig6, M. Hod7, T. Jia5, B. Kalyanam8, S. Kar8, A. Kautzky-Willer9, P. Damm1,2   +11 more
semanticscholar   +1 more source

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]

, 2018
Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V., Goodwill, Adam, Green, Mark A., Hamilton, LaTonya, Hutchins, Gary D., Mather, Kieren J., Mathias, Carla, Patel, Niral A., Territo, Wendy, Tune, Johnathan D.   +9 more
core   +1 more source

A Single Center, Open-Labeled Trial to Investigate the Pharmacokinetics of Insulin Detemir in Healthy Taiwanese Subjects

Journal of Drug Research and Development, 2022
Backgrounds: Insulin detemir (NN304) is a long-acting insulin analogue reported to provide more predictable blood glucose level throughout the day, leading to a lower within-subject variability compared to NPH insulin. Pharmacokinetic profiles of insulin
Kwok Cf, Ho Lt
semanticscholar   +1 more source

Comparison of insulin detemir and insulin glargine in a Basal-Bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial [PDF]

, 2009
Objective: The primary study objective was to determine whether insulin detemir (detemir) was noninferior to insulin glargine (glargine) as the basal insulin in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in terms of glycemic ...
Albright, Bolli, Bruce Bode, Buse, Christoph Koenen, Devries, Garg, Havelund, Heinemann, Heinemann, Heise, Heise, Hermansen, Hougaard, Jehle, Klein, Le Floch, Montgomery, Owens, Pieber, Ratner, Russell-Jones, Simon Heller   +22 more
core   +1 more source

All-Cause and Cardiovascular Mortality Among Insulin-Naïve People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK

Diabetes Therapy, 2021
Uncontrolled type 2 diabetes (T2D) is associated with an increased risk of micro- and macrovascular complications and mortality. The impact of basal insulins on the risks of mortality and cardiovascular mortality in people with T2D has not been ...
L. Husemoen, Lina S. Mørch, P. Christensen, N. Hartvig, M. Feher   +4 more
semanticscholar   +1 more source

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas [PDF]

, 2013
OBJECTIVEdThis multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without ...
Adetunji, O., Davies, M., Heller, S., Sapin, H., Sreenan, S., Tahbaz, A., Vora, J.   +6 more
core   +1 more source